Trending...
- Sign Up Your Pet, Feed a Family - 137
- California: Following Kristi Noem's firing, Governor Newsom demands DHS redirect funding from Noem's failed ad campaign to LA recovery
- Boxaloo Launches Load Board for Box Trucks, Sprinters, Cargo Vans, and Hotshots
SAN DIEGO--(BUSINESS WIRE)--Lassen Therapeutics, a biotech company developing breakthrough antibody therapeutics as potential treatments for immuno-fibrotic diseases and oncology, today announced the initiation of dosing in a Phase 1 study of LASN01, a novel interleukin-11 (IL-11) receptor-blocking antibody. The Phase 1 single and multiple ascending dose study will evaluate the safety, tolerability, immunogenicity, and pharmacokinetics of LASN01 in healthy volunteers.
"The initiation of this trial is an important milestone for Lassen and continues our progress towards developing a new treatment option for patients with excessive fibrosis," said Puneet Arora, MD, Chief Medical Officer of Lassen. "IL-11 plays a critical role in the initiation and maintenance of chronic fibrotic responses and as a result, blocking this pathway represents a promising approach for multiple diseases characterized by unchecked fibrosis. We believe LASN01 has best-in-class potential to block IL-11 signaling and reduce fibrosis."
The initiation of this Phase 1 trial and the LASN01 clinical program is based in part on pre-clinical data reported at the American Thoracic Society (ATS) Annual Meeting 2022. The data presented at ATS demonstrated potent blockade of IL-11-stimulated signaling by LASN01 and inhibition of TGF-β-stimulated collagen expression by patient-derived idiopathic pulmonary fibrosis (IPF) fibroblasts. In ex vivo assays using human lung tissue, LASN01 inhibited TGF-β-stimulated production of the fibrotic markers procollagen type I and tissue inhibitor of metallopeptidase 1 (TIMP1), and reduced collagen neo-epitope release from slices of diseased IPF lung tissue. Inhibition of IL-11 signaling also showed a significant anti-fibrotic effect in the lung and skin in animal models of fibrosis.
More on The Californer
More information on the Phase 1 study (NCT05331300) is available at clinicaltrials.gov.
About Lassen Therapeutics
Lassen Therapeutics develops breakthrough antibodies as potential treatments for immuno-fibrotic diseases and oncology. The company's lead candidate is LASN01, a best-in-class monoclonal antibody targeting IL-11 receptor (IL-11R). IL-11, a member of the IL-6 family of cytokines, is a central mediator of fibrosis and blocking its activity has the potential to be safer than, and additive to, other anti-fibrotic therapeutic approaches. IL-11 is also an important effector of tumor microenvironment organization, playing a key role as a mediator between cancer and stromal cells. The company is also developing a novel immuno-oncology therapeutic targeting interleukin-18 binding protein (IL-18BP), a checkpoint on IL-18 activity. Our antibodies inhibit the checkpoint activity of IL-18BP to allow IL-18 to stimulate multiple immune cell populations including enhancement of NK and T cell mediated immune responses to tumors. The program is at lead optimization stage.
More on The Californer
For more information, please visit www.lassentherapeutics.com.
Contacts
Media:
Christine Quern
CBQ Communications
cq@christinequern.com
617.650.8497
"The initiation of this trial is an important milestone for Lassen and continues our progress towards developing a new treatment option for patients with excessive fibrosis," said Puneet Arora, MD, Chief Medical Officer of Lassen. "IL-11 plays a critical role in the initiation and maintenance of chronic fibrotic responses and as a result, blocking this pathway represents a promising approach for multiple diseases characterized by unchecked fibrosis. We believe LASN01 has best-in-class potential to block IL-11 signaling and reduce fibrosis."
The initiation of this Phase 1 trial and the LASN01 clinical program is based in part on pre-clinical data reported at the American Thoracic Society (ATS) Annual Meeting 2022. The data presented at ATS demonstrated potent blockade of IL-11-stimulated signaling by LASN01 and inhibition of TGF-β-stimulated collagen expression by patient-derived idiopathic pulmonary fibrosis (IPF) fibroblasts. In ex vivo assays using human lung tissue, LASN01 inhibited TGF-β-stimulated production of the fibrotic markers procollagen type I and tissue inhibitor of metallopeptidase 1 (TIMP1), and reduced collagen neo-epitope release from slices of diseased IPF lung tissue. Inhibition of IL-11 signaling also showed a significant anti-fibrotic effect in the lung and skin in animal models of fibrosis.
More on The Californer
- Vallejo Housing Market Gives Buyers Something They Haven't Seen in a While: Breathing Room
- Where to Find the Best Furniture Deals in LA: Sabi Goods Offers 60-90% Off Luxury Brands
- ABLD.app Launches Digital Blue Envelope Profiles to Streamline ADA Accommodation Requests
- American Properties Realty, Inc. Leadership Attends NAHB International Builders' Show in Florida
- San Diego's Leading Digital Marketing Agency California Web Coders Helps Businesses Achieve Online G
More information on the Phase 1 study (NCT05331300) is available at clinicaltrials.gov.
About Lassen Therapeutics
Lassen Therapeutics develops breakthrough antibodies as potential treatments for immuno-fibrotic diseases and oncology. The company's lead candidate is LASN01, a best-in-class monoclonal antibody targeting IL-11 receptor (IL-11R). IL-11, a member of the IL-6 family of cytokines, is a central mediator of fibrosis and blocking its activity has the potential to be safer than, and additive to, other anti-fibrotic therapeutic approaches. IL-11 is also an important effector of tumor microenvironment organization, playing a key role as a mediator between cancer and stromal cells. The company is also developing a novel immuno-oncology therapeutic targeting interleukin-18 binding protein (IL-18BP), a checkpoint on IL-18 activity. Our antibodies inhibit the checkpoint activity of IL-18BP to allow IL-18 to stimulate multiple immune cell populations including enhancement of NK and T cell mediated immune responses to tumors. The program is at lead optimization stage.
More on The Californer
- California: Governor Newsom announces more than $23 million to increase access to farm-fresh food for CalFresh, WIC, and Senior Farmers' Market Nutrition Program recipients
- Professional San Diego Web Design Service Custom Website Solution: California Web Coders Helps Busi
- Digital Marketing & Web Experts CA: California Web Coders Helps Businesses Grow Online in 2026
- UCLA Black Alumni Association Hosts 2026 Winston C. Doby Legacy Scholarship Gala
- Top Rated San Diego Web Design Agency: California Web Coders Driving Digital Growth for Businesses
For more information, please visit www.lassentherapeutics.com.
Contacts
Media:
Christine Quern
CBQ Communications
cq@christinequern.com
617.650.8497
Filed Under: Business
0 Comments
Latest on The Californer
- Meet and Greet Award Winning Authors Lizzy Stevens and Steve Miller
- The "Unsexy" Business Quietly Creating 130+ New Entrepreneurs Across America — From Alaska to Puerto Rico
- Veteran Launches GTG Energy: Nicotine-Free Pouch as Americans Rethink Addiction, Focus, and What Fuels Performance
- San Diego Mental Health Clinic Expands Access to Structured Intensive Outpatient Care for Adults
- Organic Spray Tanning Continues to Rise in Popularity Among San Diego Residents
- California: Governor Newsom announces appointments 3.10.2026
- Learn Window Tinting with The Tint Academy in Los Angeles, California
- Kahana Feld Announces Key Partner Addition and Expansion into Pennsylvania
- 3C Gallery Presents UNSEEN, a Photography Exhibit at LMF Gallery Sierra Madre CA
- California: Governor Newsom proclaims AmeriCorps Week
- Kid's Portal Launches Ad-Free Learning App for Kids Ages 5 to 10
- Sign Up Your Pet, Feed a Family
- RecallSentry™ App Launch — Your Home Safety Hub — Free on iOS & Android
- Award-Winning Director Crystal J. Huang's Under-$50K Film "The Ritual House" Wins Best Horror Feature at Golden State Film Festival
- Grads aren't getting hired — here's what we're doing about it
- California: Governor Gavin Newsom & Attorney General Bonta: 37 Missing Children Found in Riverside County Operation
- Sovereign Authority Enacts Global Reconstitution; Mobilizes $403.875 Quadrillion Asset Deployment
- California's organized retail crime efforts result in 33,000+ stolen goods recovered in two months
- K2 Integrity Enhances Technology Capabilities Through Acquisition of Leviathan Security Group
- #WeAreGreekWarriors Comes to Detroit in Celebration of Women's History Month